Global Cardiac Stent Market Size By Type (Balloon Expandable Stents, Self-Expanding Stents), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Cardiac Stent Market was valued at USD 10.4 billion in 2023 and is projected to reach USD 17.6 billion by 2031, expanding at a CAGR of 6.7% during the forecast period from 2023 to 2031. The growth is driven by the increasing prevalence of cardiovascular diseases (CVDs), advancements in stent technology such as bioresorbable and drug-eluting stents, and rising awareness of early disease detection and treatment. The aging global population and a sedentary lifestyle are further elevating the need for minimally invasive cardiac procedures, bolstering market demand.

Drivers:

Rising Cardiovascular Disease Burden:

Globally, the prevalence of heart-related ailments continues to rise due to factors such as obesity, hypertension, diabetes, and poor lifestyle choices. Cardiac stents are essential for restoring blood flow in blocked arteries, making them a frontline intervention for coronary artery disease.

Technological Advancements in Stent Design:

The shift from bare-metal to drug-eluting and bioresorbable stents has significantly reduced restenosis rates and improved patient outcomes. Innovations like biodegradable polymers, improved drug coatings, and personalized stenting are propelling market growth.

Growing Geriatric Population:

The elderly population, which is more susceptible to coronary artery disease, is expanding worldwide. This demographic trend is creating consistent demand for cardiac stent procedures.

Restraints:

High Cost of Advanced Stents and Procedures:

Despite clinical benefits, the high cost of next-generation stents and associated interventional procedures can limit accessibility, particularly in low- and middle-income countries.

Product Recalls and Safety Concerns:

Instances of product recalls due to manufacturing defects or adverse effects can harm market trust and negatively impact adoption rates.

Opportunity:

Expansion in Emerging Markets:

Countries across Asia-Pacific and Latin America are witnessing significant healthcare infrastructure developments, offering vast potential for cardiac stent manufacturers.

Integration of AI in Cardiovascular Imaging:

The combination of AI with angiography and cardiac imaging for stent placement optimization opens new opportunities for procedural efficiency and precision.

Market by System Type Insights:

By system type, Drug-Eluting Stents (DES) accounted for the largest market share in 2023, driven by their superior efficacy in preventing restenosis. DES offers controlled drug release and superior endothelial healing, making them a preferred choice for interventional cardiologists. However, Bioresorbable Vascular Scaffolds (BVS) are expected to witness the fastest growth during the forecast period due to their ability to restore natural vascular function after resorption.

Market by End-use Insights:

Hospitals emerged as the dominant end-user segment in 2023, owing to the high volume of cardiovascular procedures performed in these settings, as well as access to advanced cardiac care technologies and skilled interventional cardiologists. The ambulatory surgical centers (ASCs) segment is projected to grow rapidly, supported by a shift toward outpatient cardiac procedures and shorter recovery times.

Market by Regional Insights:

North America led the global cardiac stent market in 2023, accounting for the highest revenue share, attributed to advanced healthcare infrastructure, widespread adoption of next-generation stents, and a high prevalence of cardiovascular disorders. Asia-Pacific is projected to experience the highest CAGR during the forecast period, driven by a growing patient population, increasing health expenditure, and supportive regulatory environments in countries like India, China, and Japan.

Competitive Scenario:

Key players in the Global Cardiac Stent Market include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, B. Braun Melsungen AG, Terumo Corporation, Biosensors International Group, and Biotronik SE & Co. KG. These companies are engaged in strategic acquisitions, product innovation, and geographic expansion.

In 2023, Abbott received expanded FDA approval for its latest-generation drug-eluting stent optimized for small vessels.

Boston Scientific launched a new iteration of its Synergy XD DES platform in 2024, enhancing radial strength and deliverability.

Medtronic initiated clinical trials in 2025 to evaluate its novel bioresorbable stent technology, aiming for global regulatory submission.

Scope of Work – Global Cardiac Stent Market

Report Metric Details

Market Size (2023) USD 10.4 billion

Projected Market Size (2031) USD 17.6 billion

CAGR (2023–2031) 6.7%

Market Segments By System Type (DES, BMS, BVS), By End-use

Growth Drivers Rising CVD burden, technological innovations, aging population

Opportunities Emerging market expansion, AI-guided stenting

Key Market Developments:

2023: Abbott received CE Mark for its next-gen bioresorbable stent with improved deliverability.

2024: Boston Scientific expanded its coronary portfolio through the acquisition of a digital stent navigation technology company.

2025: Medtronic launched AI-driven imaging software to support interventional cardiologists in complex PCI procedures.

FAQs:

1) What is the current market size of the Global Cardiac Stent Market?

The market was valued at USD 10.4 billion in 2023.

2) What is the major growth driver of the Global Cardiac Stent Market?

The increasing prevalence of cardiovascular